
On Wednesday, November 12, CAC2 had the privilege of hosting Jeffrey Skolnik, MD, US Medical Affairs Leader, Oncology, GlaxoSmithKline and Attending Physician, Children’s Hospital of Philadelphia.
He presented our November All-Member webinar about the industry perspective in pediatric oncology drug development. The views he expresses are his personal observations and not the official position of GSK or any other pharmaceutical company.
Categories
- Blog Posts (68)
- Guest Blogs (17)
- Member Blogs (27)
- Survivorship Matters Blog (9)
- CAC2 News (22)
- Collaborative Achievements (13)
- Community News (198)
- News Digest (155)
- Research Explained (10)
- Webinars (62)
Tags
#CancelChildhoodCancer (1)
Advocacy (48)
Annual Summit (7)
Appropriations (1)
Awareness (20)
AYA (2)
Best Practices (12)
Biorepositories (2)
CAC2 News (8)
CAC2 Project Incubator (1)
CAC2 Projects (11)
Call to Action (24)
Cancer Moonshot (1)
Clinical Trials (10)
COG (2)
Collaboration (11)
Comparative Oncology (1)
Data (15)
Delayed Diagnosis (2)
Digest (12)
Drug Development (12)
Drug Shortages (2)
Ethics (1)
Family Support (14)
FDA (1)
Funding Research (6)
Genomics (6)
Industry Perspective (5)
Member Access (12)
NCI (3)
Nutrition (2)
Patient-Reported Outcomes (1)
Prevention (5)
Psychosocial Support (4)
Rare and Ultra Rare Cancer (1)
Rare Cancers (1)
Regulations (3)
Research (38)
Research Advocacy (1)
Survivorship (26)
Venture Philanthropy (3)
Recent Posts
- CAC2 Childhood Cancer Community News Digest (November 27-December 3)
- CAC2 Childhood Cancer Community News Digest (November 20-26)
- CAC2 Childhood Cancer Community News Digest (November 13-19)
- CAC2 Childhood Cancer Community News Digest (November 6-12)
- Fueling the Lifelong Fight Against Childhood Cancer: Nutrition for Patients and Survivors